Welcome to our dedicated page for Stoke Therapeutics SEC filings (Ticker: STOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the real story behind Stoke Therapeutics’ next-generation RNA medicines isn’t easy—each 10-K details complex TANGO science, shifting R&D spend and cash runway nuances that can sway valuations overnight. If you have ever searched for Stoke Therapeutics SEC filings explained simply and come away with more questions than answers, this page is built for you.
Stock Titan’s AI sifts through every newly posted record on EDGAR, from a Stoke Therapeutics quarterly earnings report 10-Q filing to a sudden Stoke Therapeutics 8-K material events explained, then delivers plain-English summaries and red-flag alerts. Need to track Stoke Therapeutics insider trading Form 4 transactions or want Stoke Therapeutics Form 4 insider transactions real-time? Our platform surfaces those moves seconds after executives file, so you never miss a signal. Key takeaways from the Stoke Therapeutics annual report 10-K simplified—pipeline milestones, IP updates, liquidity outlook—are highlighted automatically, while footnotes are linked to clear definitions for faster context.
Investors typically drill into SEC documents for three reasons:
- Gauge R&D progress and upcoming FDA milestones via 10-Q trends and 8-K trial readouts.
- Monitor capital needs, dilution risk and Stoke Therapeutics proxy statement executive compensation structures.
- Spot conviction signals in Stoke Therapeutics executive stock transactions Form 4.
Whether you want a quick Stoke Therapeutics earnings report filing analysis or are understanding Stoke Therapeutics SEC documents with AI for deeper due diligence, Stock Titan offers real-time updates, expert annotations and machine-generated bullet-point briefs—all without wading through hundreds of biotech-specific pages.
Amendment No. 5 to Schedule 13D updates the ownership position of the reporting group — Skorpios Trust, Montrago Trustees Ltd., Blue Horizon Enterprise Ltd. and Ezbon International Ltd. — in Stoke Therapeutics (STOK).
The group now reports beneficial ownership of roughly 6.23 million shares, or 11.4 % of the 54.6 million shares outstanding as disclosed in STOK’s 30 April 2025 10-Q. Current individual blocks are:
- Blue Horizon: 2,967,621 shares (5.4 %) with shared voting/dispositive power
- Montrago Trustees & Skorpios Trust: 3,256,181 shares each, reflecting the same 6 % stake held jointly
- Ezbon International: 288,560 shares (0.5 %)
Key event: On 18 June 2025 Ezbon sold 650,000 shares at $11.00 in an open-market trade, cutting its holdings by ~69 % and raising about $7.2 million. No other trades were reported within the past 60 days.
A new Joint Filing Agreement dated 23 June 2025 is filed as Exhibit 1. Aside from Ezbon’s sale, prior disclosures remain unchanged.
While the group continues to exceed the 10 % threshold, Ezbon’s sizable disposal may signal reduced conviction or liquidity needs, and could introduce incremental supply pressure if additional sales follow. Investors should monitor forthcoming filings for further changes to this concentrated insider position.
Stoke Therapeutics (STOK) – Form 3 initial beneficial ownership disclosure
Chief Patient Officer Jason Hoitt has filed his first Section 16 statement. He directly owns 1,802 common shares of Stoke Therapeutics. In addition, he holds 480,000 employee stock options across four grants: 265,000 options at $12.21 expiring 04/14/2034; 65,000 at $14.25 expiring 08/14/2034; 60,000 at $8.33 expiring 03/19/2035; and 90,000 at $11.70 expiring 06/15/2035. Vesting schedules follow the standard 25% cliff after one year, with the remainder vesting monthly, subject to continued employment. Hoitt was also granted 40,000 restricted stock units (RSUs) that vest 25% annually starting 03/15/2026.
The filing is informational only—no shares were bought or sold. While the equity package is meaningful for the executive, it represents a small fraction of the company’s total shares outstanding and is unlikely to move the market. Nonetheless, the disclosure demonstrates alignment of management incentives with shareholder interests.
FAQ
What is the current stock price of Stoke Therapeutics (STOK)?
What is the market cap of Stoke Therapeutics (STOK)?
